(NOVC.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:NOVC - DK0060534915 - Common Stock
86.34 EUR
-2.03 (-2.3%)
Taking everything into account, NOVC scores 7 out of 10 in our fundamental rating. NOVC was compared to 55 industry peers in the Pharmaceuticals industry. NOVC gets an excellent profitability rating and is at the same time showing great financial health properties. NOVC is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make NOVC a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
NOVC had positive earnings in the past year.
In the past year NOVC had a positive cash flow from operations.
NOVC had positive earnings in each of the past 5 years.
In the past 5 years NOVC always reported a positive cash flow from operatings.
1.2 Ratios
NOVC has a Return On Assets of 23.95%. This is amongst the best in the industry. NOVC outperforms 95.56% of its industry peers.
NOVC has a better Return On Equity (74.32%) than 95.56% of its industry peers.
With an excellent Return On Invested Capital value of 55.96%, NOVC belongs to the best of the industry, outperforming 97.78% of the companies in the same industry.
NOVC had an Average Return On Invested Capital over the past 3 years of 49.65%. This is significantly above the industry average of 13.92%.
The last Return On Invested Capital (55.96%) for NOVC is above the 3 year average (49.65%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| ROIC | 55.96% |
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
1.3 Margins
With an excellent Profit Margin value of 33.40%, NOVC belongs to the best of the industry, outperforming 91.11% of the companies in the same industry.
In the last couple of years the Profit Margin of NOVC has declined.
NOVC has a Operating Margin of 42.80%. This is amongst the best in the industry. NOVC outperforms 95.56% of its industry peers.
In the last couple of years the Operating Margin of NOVC has remained more or less at the same level.
NOVC has a Gross Margin of 84.35%. This is amongst the best in the industry. NOVC outperforms 84.44% of its industry peers.
NOVC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.8% | ||
| PM (TTM) | 33.4% | ||
| GM | 84.35% |
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NOVC is creating value.
The number of shares outstanding for NOVC has been reduced compared to 1 year ago.
Compared to 1 year ago, NOVC has an improved debt to assets ratio.
2.2 Solvency
NOVC has an Altman-Z score of 11.18. This indicates that NOVC is financially healthy and has little risk of bankruptcy at the moment.
NOVC has a better Altman-Z score (11.18) than 93.33% of its industry peers.
The Debt to FCF ratio of NOVC is 0.38, which is an excellent value as it means it would take NOVC, only 0.38 years of fcf income to pay off all of its debts.
NOVC's Debt to FCF ratio of 0.38 is amongst the best of the industry. NOVC outperforms 91.11% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that NOVC is not too dependend on debt financing.
NOVC's Debt to Equity ratio of 0.21 is in line compared to the rest of the industry. NOVC outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 0.38 | ||
| Altman-Z | 11.18 |
ROIC/WACC7.69
WACC7.28%
2.3 Liquidity
A Current Ratio of 0.88 indicates that NOVC may have some problems paying its short term obligations.
NOVC has a Current ratio of 0.88. This is amonst the worse of the industry: NOVC underperforms 84.44% of its industry peers.
NOVC has a Quick Ratio of 0.88. This is a bad value and indicates that NOVC is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.70, NOVC is not doing good in the industry: 82.22% of the companies in the same industry are doing better.
The current and quick ratio evaluation for NOVC is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
The earnings per share for NOVC have decreased strongly by -32.68% in the last year.
Measured over the past 5 years, NOVC shows a small growth in Earnings Per Share. The EPS has been growing by 3.48% on average per year.
Looking at the last year, NOVC shows a very strong growth in Revenue. The Revenue has grown by 28.03%.
Measured over the past years, NOVC shows a quite strong growth in Revenue. The Revenue has been growing by 9.64% on average per year.
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
3.2 Future
Based on estimates for the next years, NOVC will show a very strong growth in Earnings Per Share. The EPS will grow by 25.79% on average per year.
NOVC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.65% yearly.
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 43.17, the valuation of NOVC can be described as expensive.
Based on the Price/Earnings ratio, NOVC is valued a bit more expensive than the industry average as 64.44% of the companies are valued more cheaply.
NOVC is valuated expensively when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 15.13, NOVC is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NOVC indicates a somewhat cheap valuation: NOVC is cheaper than 64.44% of the companies listed in the same industry.
NOVC is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.22, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.17 | ||
| Fwd PE | 15.13 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NOVC is valued a bit more expensive than the industry average as 64.44% of the companies are valued more cheaply.
NOVC's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.68 | ||
| EV/EBITDA | 30.33 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NOVC has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NOVC's earnings are expected to grow with 40.31% in the coming years.
PEG (NY)0.45
PEG (5Y)12.41
EPS Next 2Y52.67%
EPS Next 3Y40.31%
5. Dividend
5.1 Amount
NOVC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap386.28B
Revenue(TTM)201.32B
Net Income(TTM)67.24B
Analysts70.63
Price Target169.94 (96.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP41.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.26%
Min EPS beat(2)-6.63%
Max EPS beat(2)2.11%
EPS beat(4)3
Avg EPS beat(4)-0.09%
Min EPS beat(4)-6.63%
Max EPS beat(4)2.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)99180.3%
Min Revenue beat(2)97265.9%
Max Revenue beat(2)101095%
Revenue beat(4)4
Avg Revenue beat(4)100079%
Min Revenue beat(4)97265.9%
Max Revenue beat(4)101151%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.68%
PT rev (3m)6.75%
EPS NQ rev (1m)-50.34%
EPS NQ rev (3m)-49.42%
EPS NY rev (1m)0.22%
EPS NY rev (3m)4.6%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.9%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)3.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.17 | ||
| Fwd PE | 15.13 | ||
| P/S | 14.31 | ||
| P/FCF | 42.68 | ||
| P/OCF | 32.1 | ||
| P/B | 31.84 | ||
| P/tB | 72.51 | ||
| EV/EBITDA | 30.33 |
EPS(TTM)2
EY2.32%
EPS(NY)5.71
Fwd EY6.61%
FCF(TTM)2.02
FCFY2.34%
OCF(TTM)2.69
OCFY3.12%
SpS6.03
BVpS2.71
TBVpS1.19
PEG (NY)0.45
PEG (5Y)12.41
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| ROCE | 69.41% | ||
| ROIC | 55.96% | ||
| ROICexc | 79.18% | ||
| ROICexgc | 187.85% | ||
| OM | 42.8% | ||
| PM (TTM) | 33.4% | ||
| GM | 84.35% | ||
| FCFM | 33.53% |
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
ROICexc(3y)59.43%
ROICexc(5y)70.56%
ROICexgc(3y)107.14%
ROICexgc(5y)103.87%
ROCE(3y)66.16%
ROCE(5y)72.5%
ROICexgc growth 3Y12.28%
ROICexgc growth 5Y2.92%
ROICexc growth 3Y-8.96%
ROICexc growth 5Y-9.74%
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
F-Score7
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 0.38 | ||
| Debt/EBITDA | 0.21 | ||
| Cap/Depr | 278.9% | ||
| Cap/Sales | 11.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 100.38% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 11.18 |
F-Score7
WACC7.28%
ROIC/WACC7.69
Cap/Depr(3y)235.6%
Cap/Depr(5y)244.27%
Cap/Sales(3y)10.33%
Cap/Sales(5y)10.26%
Profit Quality(3y)95.36%
Profit Quality(5y)92.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
EBIT growth 1Y29.73%
EBIT growth 3Y12.1%
EBIT growth 5Y8.94%
EBIT Next Year38.11%
EBIT Next 3Y23.19%
EBIT Next 5Y17.5%
FCF growth 1Y112.16%
FCF growth 3Y21.73%
FCF growth 5Y14.55%
OCF growth 1Y65.59%
OCF growth 3Y19.03%
OCF growth 5Y13.89%
/ NOVC.DE FAQ
What is the ChartMill fundamental rating of (NOVC.DE) stock?
ChartMill assigns a fundamental rating of 7 / 10 to NOVC.DE.
Can you provide the valuation status for ?
ChartMill assigns a valuation rating of 4 / 10 to (NOVC.DE). This can be considered as Fairly Valued.
How profitable is (NOVC.DE) stock?
(NOVC.DE) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for NOVC stock?
The Earnings per Share (EPS) of (NOVC.DE) is expected to grow by 96.77% in the next year.
Can you provide the dividend sustainability for NOVC stock?
The dividend rating of (NOVC.DE) is 4 / 10 and the dividend payout ratio is 41.57%.